Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 79 citing articles:

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
Antonio Russo, Marcello Silvestro, Fabrizio Scotto di Clemente, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 121
Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
Lucas Hendrik Overeem, Andreas Peikert, Maxi Dana Hofacker, et al.
Cephalalgia (2021) Vol. 42, Iss. 4-5, pp. 291-301
Open Access | Times Cited: 93
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
Luigi Francesco Iannone, Davide Fattori, Silvia Benemei, et al.
CNS Drugs (2022) Vol. 36, Iss. 2, pp. 191-202
Open Access | Times Cited: 62
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study
Christopher Kjær Cullum, Thien Phu, Messoud Ashina, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 47
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 40
New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy
Mi Ji Lee, Mohammad Al‐Mahdi Al‐Karagholi, Uwe Reuter
Cephalalgia (2023) Vol. 43, Iss. 2
Open Access | Times Cited: 28
Resistant and refractory migraine: clinical presentation, pathophysiology, and management
Raffaele Ornello, Anna P. Andreou, Eleonora De Matteis, et al.
EBioMedicine (2023) Vol. 99, pp. 104943-104943
Open Access | Times Cited: 26
Association between response to triptans and response to erenumab: real-life data
Ilaria Frattale, Valeria Caponnetto, Alfonsina Casalena, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 51
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
Simona Sacco, Christian Lampl, Antoinette MaassenVanDenBrink, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 49
Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
Simone de Vries Lentsch, Iris E. Verhagen, Thomas C. van den Hoek, et al.
European Journal of Neurology (2021) Vol. 28, Iss. 12, pp. 4194-4203
Open Access | Times Cited: 47
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis
Lucas Hendrik Overeem, Bianca Raffaelli, Jasper Mecklenburg, et al.
CNS Drugs (2021) Vol. 35, Iss. 8, pp. 805-820
Open Access | Times Cited: 45
Predictors of response to erenumab after 12 months of treatment
Carlo Baraldi, Flavia Lo Castro, Maria Michela Cainazzo, et al.
Brain and Behavior (2021) Vol. 11, Iss. 8
Open Access | Times Cited: 44
Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
Jamie Talbot, Rebecca Stuckey, Louise Crawford, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 43
Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache
Umberto Pensato, Carlo Baraldi, Valentina Favoni, et al.
Neurological Sciences (2021) Vol. 43, Iss. 2, pp. 1273-1280
Closed Access | Times Cited: 41
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
Raffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 34
Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
Bianca Raffaelli, Maria Terhart, Jasper Mecklenburg, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 30
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
Umberto Pensato, Carlo Baraldi, Valentina Favoni, et al.
Cephalalgia (2022) Vol. 42, Iss. 7, pp. 645-653
Open Access | Times Cited: 29
Erenumab in Chronic Migraine: An Australian Experience
Shuli Cheng, Bronwyn Jenkins, Nicole Limberg, et al.
Headache The Journal of Head and Face Pain (2020) Vol. 60, Iss. 10, pp. 2555-2562
Closed Access | Times Cited: 45
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
Raffaele Ornello, Alfonsina Casalena, Ilaria Frattale, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 41
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
R. Belvís, Pablo Irimia, Patricia Pozo‐Rosich, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 39
Refractory migraine
Г. Р. Табеева, O. V. Kosivtsova, N. A. Kovalchuk, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 2, pp. 76-86
Open Access | Times Cited: 5
Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review
Ann Murray, Jennifer I. Stern, Carrie E. Robertson, et al.
Current Pain and Headache Reports (2022) Vol. 26, Iss. 10, pp. 783-794
Closed Access | Times Cited: 21
Switching between anti-cgrp monoclonal antibodies in migraine prophylaxis
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study
Maria Michela Cainazzo, Carlo Baraldi, Anna Ferrari, et al.
Neurological Sciences (2021) Vol. 42, Iss. 10, pp. 4193-4202
Closed Access | Times Cited: 27
Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
Jean Schoenen, Grégory Timmermans, Romain Nonis, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top